7 results about "Levocetrizine" patented technology

The present invention relates to solid compositions. The present invention addresses the problem of providing a solid composition containing at least one substance selected from the group consisting of tepiperidine and salts thereof, and at least one substance selected from the group consisting of tranexamic acid and salts thereof, in which the dissolution of tepiperidine is improved. [Solution] A solid composition containing the following components: (A) at least one substance selected from the group consisting of tepiperidine and salts thereof; (B) at least one substance selected from the group consisting of tranexamic acid and salts thereof; and (C) at least one compound selected from the group consisting of ibuprofen and salts thereof, in which the solid composition does not include a solid composition comprising levocetirizine or loratadine.

The present invention relates to solid compositions. The present invention addresses the problem of providing a solid composition containing ibuprofen in which changes in properties are suppressed. [Solution] A solid composition comprising the following components: (A) ibuprofen; (B) at least one substance selected from the group consisting of tepiperidine and salts thereof; and (C) at least one compound selected from the group consisting of tranexamic acid and salts thereof, in which the solid composition does not include a solid composition containing levocetirizine or loratadine.

Described herein is a method of administering injectable cetirizine or levocetirizine to treat acute urticaria, with or without concomitant angioedema, without life-threatening airway swelling by intravenously injecting a human patient within minutes to hours of developing acute urticaria in an emergency department or clinic with a therapeutically effective amount of an injectable cetirizine or levocetirizine composition. In the method, the injectable cetirizine or levocetirizine is the only treatment administered in the emergency department or clinic. The method can include determining, by the patient, a patient rated pruritus severity score at a 1 hour assessment, and optionally at a 2 hours assessment, and a physician discharging the human patient after 1.7±0.9 hours in the emergency department or clinic, wherein the human patient has a patient rated pruritus severity score reduction of at least 1 unit and baseline sedation at the time of discharge.

Certain embodiments described herein include methods and formulations for treating or preventing symptoms and conditions associated with sepsis. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and / or modified-release elements, providing for drug delivery to the patient.

The application discloses a preparation method and application of a levocetirizine hydrochloride intermediate, and a high-quality levocetirizine hydrochloride intermediate is obtained. The method comprises the following steps: taking di(2-chloroethyl)amine as a raw material, performing a formate esterification reaction, performing a (R)-(4-chlorophenyl)(phenyl)methylamine cyclization, and performing reduction to obtain the levocetirizine hydrochloride intermediate, and then performing a substitution reaction to generate the levocetirizine hydrochloride. The method is simple in operation, has less by-product, has a high yield, is easy in raw material obtaining, is low in cost, and is suitable for industrial large-scale production.

To provide a solid composition containing ibuprofen, the change in properties of which is suppressed. The present invention relates to a composition comprising: (A) Ibuprofen, (B) at least one selected from the group consisting of tipepidine and salts thereof, and (C) at least one selected from the group consisting of tranexamic acid and salts thereof A solid composition comprising, but excluding a solid composition comprising levocetirizine or loratadine.

To provide a solid composition containing at least one selected from the group consisting of tipepidine and salts thereof and at least one selected from the group consisting of tranexamic acid and salts thereof, which has improved dissolution properties of tipepidine. The present invention relates to a composition comprising the following components: (A) at least one selected from the group consisting of tipepidine and salts thereof, (B) at least one selected from the group consisting of tranexamic acid and salts thereof, and (C) at least one selected from the group consisting of ibuprofen and salts thereof A solid composition comprising, but excluding a solid composition comprising levocetirizine or loratadine.